Finance

Beta
Lists
ELVN:NASDAQ
Enliven Therapeutics Inc
$47.77
-1.71%
(-0.83) 1D
$47.60
-0.36% (-0.17)
After hours
Closed: Jun 24, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ELVN...
Open
$48.68
High
$49.94
Low
$45.01
Mkt. cap
3.34B
Avg. vol.
1.50M
Volume
0.00
52-wk high
$49.94
52-wk low
$14.78
EPS
-$1.66
Beta
0.29
Shares outstanding
69.84M
No. of employees
61
Open
$48.68
High
$49.94
Low
$45.01
Mkt. cap
3.34B
Avg. vol.
1.50M
Volume
0.00
52-wk high
$49.94
52-wk low
$14.78
EPS
-$1.66
Beta
0.29
Shares outstanding
69.84M
No. of employees
61
News stories
From sources across the web
About Enliven Therapeutics Inc
CEO-
Employees61
Founded2016
HeadquartersBoulder, Colorado, United States
SectorPharmaceutical industry
Websiteimaratx.com
Analyst Ratings
Based on 10 analysts giving stock ratings to ELVN in the past 3 months
Strong Buy
Buy
10
Hold
0
Sell
0
12 month forecast
Based on 10 Wall Street analysts offering 12 month price targets for ELVN in the last 3 months.
Highest
Current $47.77
$80.00 (+67.47%)
Average
$59.56 (+24.68%)
Lowest
$45.00 (-5.80%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Unknown Analyst
Jefferies
Buy
Maintained
$59.00
+23.5%
06/15/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
06/11/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$80.00
+67.5%
06/12/2026
Sam Slutsky
LifeSci Capital
Buy
Reiterated
$60.00
+25.6%
06/11/2026
Boris Peaker
JonesTrading
Buy
Reiterated
$45.00
-5.8%
06/11/2026
Dara Azar
Stifel Nicolaus
Buy
Initiated
$60.00
+25.6%
06/09/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$59.00
+23.5%
06/04/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$62.00
+29.8%
06/02/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$56.00
+17.2%
05/11/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$55.00
+15.1%
04/27/2026
Soumit Roy
JonesTrading
Buy
Maintained
$45.00
-5.8%
04/06/2026
Last report
May 7, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.38 / -$0.41
+7.32%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
21.49M
18.22M
21.24M
20.69M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.09M
6.87M
13.04M
7.14M
Operating expense
28.58M
25.10M
34.28M
27.82M
Total operating expenses
28.58M
25.10M
34.28M
27.82M
Operating income
-28.58M
-25.10M
-34.28M
-27.82M
Other non operating income
-2.00K
-
-
-
EBT including unusual items
-25.34M
-20.15M
-29.67M
-23.63M
EBT excluding unusual items
-25.34M
-20.15M
-29.67M
-23.63M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-25.34M
-20.15M
-29.67M
-23.63M
Net profit margin
-
-
-
-
Earnings per share
-0.49
-0.32
-0.48
-0.38
Interest and investment income
3.25M
4.95M
4.62M
4.20M
Interest expense
-
-
-
-
Net interest expenses
3.25M
4.95M
4.62M
4.20M
Depreciation and amortization charges
-
-
-
-
EBITDA
-28.50M
-25.03M
-34.24M
-27.81M
Gain or loss from assets sale
-
-
106.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer